Continuous glucose monitoring represents the largest single portable diagnostic device category by patient utilization, with the US Portable Diagnostic Devices Market reflecting the explosive commercial growth of Dexcom G7, Abbott FreeStyle Libre 3, and Medtronic Guardian 4 systems that have transformed diabetes management from intermittent fingerstick glucose testing toward continuous real-time glucose monitoring for both type 1 and type 2 diabetes.

CGM adoption has accelerated through coverage expansion — Medicare coverage for CGM in intensive insulin users followed by expanded coverage for all insulin-treated diabetes — combined with the clinical evidence demonstrating superior glycemic outcomes, reduced hypoglycemia, and improved quality of life compared to fingerstick self-monitoring. The ADA's recommendation of CGM as preferred monitoring for all people with type 1 diabetes and for insulin-treated type 2 diabetes reflects the paradigm shift from intermittent to continuous monitoring.

Abbott FreeStyle Libre 3's fourteen-day wear sensor with one-hour factory calibration and one-minute reading interval — combined with the Libre 3's smallest CGM sensor at its launch — has achieved the largest global CGM market share through the combination of convenience, durability, and competitive pricing that makes CGM accessible to the broader insulin-treated diabetes population beyond the highest-risk intensive management patients who historically received CGM first.

CGM expansion beyond diabetes — investigating CGM use in non-diabetic individuals for metabolic health optimization, prediabetes identification, and precision nutrition — represents the consumer wellness CGM market that Levels Health and similar companies are developing, using CGM data to personalize dietary recommendations based on individual postprandial glucose response patterns.

Do you think CGM will eventually replace fingerstick testing entirely for all insulin-treated diabetes patients, or will accuracy limitations maintain a role for confirmatory fingerstick testing?

FAQ

What is continuous glucose monitoring? CGM systems use a small sensor inserted under the skin measuring interstitial glucose continuously, transmitting readings every one to five minutes to a receiver or smartphone; they alert users to high and low glucose trends, enabling more proactive glucose management than intermittent fingerstick testing.

Does Medicare cover CGM devices? Medicare covers CGM for beneficiaries with diabetes who are treated with intensive insulin regimens; coverage was expanded to all insulin-treated Medicare beneficiaries following evidence demonstrating CGM's clinical benefit in reducing hypoglycemia and improving glycemic control.

#USPortableDiagnostics #CGM #ContinuousGlucose #DexcomG7 #FreestyleLibre #DiabetesMonitoring